Download PDF
Klin Monbl Augenheilkd 2014; 231(5): 548-553
DOI: 10.1055/s-0034-1368422
Statement
Georg Thieme Verlag KG Stuttgart · New York

Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie der chorioidalen Neovaskularisation bei Myopie (Stand: März 2014)

D. Pauleikhoff
1   Augenabteilung, St. Franziskus Hospital, Münster
,
B. Bertram
2   Augenarztpraxis, Köln
,
D. Claessens
3   Augenarztpraxis, Aachen
› Author Affiliations
Further Information

Publication History

Publication Date:
05 May 2014 (online)

Also available at
    Permissions and Reprints

Die Stellungnahme fasst die derzeitigen Empfehlungen zur Therapie chorioidaler Neovaskularisationen bei Myopie zusammen. Grundlage ist eine Literaturrecherche, angelehnt an das „Manual Systematische Literaturrecherche für die Erstellung von Leitlinien, Version 1.0“ [14]. Bei der Diagnostik wird auf die aktuelle Stellungnahme „Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien“ (Ophthalmologe und Klin. Monatsblätter Febr. 2013) verwiesen ([10]; http://cms.augeninfo.de/fileadmin/stellungnahmen/Anti-VEGF-Therapie_bei_der_neovask_Therapeut_Strategie.pdf).

 

  • Literatur

  • 1 Wolf S, Balciuniene VJ, Laganovska G et al. RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014; 121: 682-692
    CrossrefPubMedGoogle Scholar
  • 2 Baba T, Kubota-Taniai M, Kitahashi M et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010; 94: 864-870
    CrossrefPubMedGoogle Scholar
  • 3 Bandello F. Twelve-month efficacy and safety of ranibizumab 0.5 mg(RBZ) versus verteporfin photodynamic therapy(vPDT) in the treatment of visual impairment(VI) due to choroidal neovascularization(CNV) secondary to pathologic myopia (PM). ARVO Abstract 2013; Program #1247.
    PubMedGoogle Scholar
  • 4 Bandello F, Parodi MB, Iacono P et al. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia. Retina 2013; 33: 593-597
    CrossrefPubMedGoogle Scholar
  • 5 Bressler NM, Arnold J, Benchaboune M et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion compositionʼs impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 2002; 120: 1443-1454
    CrossrefPubMedGoogle Scholar
  • 6 Chan A, Blumenkranz MS, Wu KH et al. Photodynamic therapy with and without adjunctive intravitreal triamcinolone acetonide: a retrospective comparative study. Ophthalmic Surg Lasers Imaging 2009; 40: 561-569
    CrossrefPubMedGoogle Scholar
  • 7 Chang L, Pan CW, Ohno-Matsui K et al. Myopia-related fundus changes in Singapore adults with high myopia. Am J Ophthalmol 2013; 155: 991-999
    CrossrefPubMedGoogle Scholar
  • 8 Cohen SY. Anti-VEGF drugs as the 2009 firstline therapy for choroidal neovascularization in pathologic myopia. Retina 2009; 29: 1062-1066
    CrossrefPubMedGoogle Scholar
  • 9 Cornut PL, Poli M, Feldman A et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month results. J Fr Ophtalmol 2010; 33: 327-333
    CrossrefPubMedGoogle Scholar
  • 10 DOG, RG, BVA. Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien. Ophthalmologe 2013; 110: 191-198
    CrossrefPubMedGoogle Scholar
  • 11 DOG, RG, BVA. Die Anti-VEGF-Therapie bei der neovaskulären altersabhängigen Makuladegeneration: Therapeutische Strategien. Klin Monatsbl Augenheilkd 2013; 230: 170-177
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 DOG, RG, BVA. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie der chorioidalen Neovaskularisation bei Myopie. Ophthalmologe 2010; 107: 494-496
    CrossrefPubMedGoogle Scholar
  • 13 DOG, RG, BVA. Aktuelle Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands „Neue Aspekte in der Therapie der neovaskulären altersabhängigen Makuladegeneration“. Ophthalmologe 2009; 106: 457-464 und Klin Monatsbl Augenheilkd 2009; 226: 388–395
    CrossrefPubMedGoogle Scholar
  • 14 Deutsches Cochrane-Zentrum, A.d.W.M.F.-I.f.M.W, Ärztliches Zentrum für Qualität in der Medizin. Manual Systematische Literaturrecherche für die Erstellung von Leitlinien. Im Internet:. http://wwwcochranede/de/webliographie-litsuche Stand: 9.12.2013
    PubMedGoogle Scholar
  • 15 Franqueira N, Cachulo ML, Pires I et al. Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab. Ophthalmologica 2012; 227: 39-44
    CrossrefPubMedGoogle Scholar
  • 16 Gharbiya M, Allievi F, Conflitti S et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter 2010; 161: e87-e93
    PubMedGoogle Scholar
  • 17 Gharbiya M, Giustolisi R, Allievi F et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab – a randomized controlled trial. Am J Ophthalmol 2010; 149: 458-464
    CrossrefPubMedGoogle Scholar
  • 18 Han DP, McAllister JT, Weinberg DV et al. Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation. Eye (Lond) 2010; 24: 713-716
    CrossrefPubMedGoogle Scholar
  • 19 Hayashi K, Ohno-Matsui K, Shimada N et al. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol 2011; 151: 137-147
    CrossrefPubMedGoogle Scholar
  • 20 Hayashi K, Ohno-Matsui K, Shimada N et al. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 2010; 117: 1595-1611
    CrossrefPubMedGoogle Scholar
  • 21 Iacono P, Parodi MB, Papayannis A et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012; 32: 1539-1546
    CrossrefPubMedGoogle Scholar
  • 22 Konstantinidis L, Mantel I, Pournaras JA et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247: 311-318
    CrossrefPubMedGoogle Scholar
  • 23 Lai TY, Chan WM, Liu DT et al. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009; 29: 750-756
    CrossrefPubMedGoogle Scholar
  • 24 Maberley D. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology 2009; 116: 2149-2157
    CrossrefPubMedGoogle Scholar
  • 25 Pan CW, Boey PY, Cheng CY et al. Myopia, axial length, and age-related cataract: the Singapore Malay eye study. Invest Ophthalmol Vis Sci 2013; 54: 4498-4502
    CrossrefPubMedGoogle Scholar
  • 26 Pan CW, Cheng CY, Saw SM et al. Myopia and age-related cataract: a systematic review and meta-analysis. Am J Ophthalmol 2013; 156: 1021-1033
    CrossrefPubMedGoogle Scholar
  • 27 Parmeggiani F, Costagliola C, Incorvaia C et al. Pharmacogenetic aspects in therapeutic management of subfoveal choroidal neovascularisation: role of factor XIII-A 185 T-allele. Curr Drug Targets 2011; 12: 138-148
    CrossrefPubMedGoogle Scholar
  • 28 Parodi MB, Iacono P, Papayannis A et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010; 128: 437-442
    CrossrefPubMedGoogle Scholar
  • 29 Ruiz-Moreno JM, Montero JA, Gomez-Ulla F. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularisation treated by intravitreal bevacizumab. Br J Ophthalmol 2009; 93: 1693-1694
    CrossrefPubMedGoogle Scholar
  • 30 Silva RM, Ruiz-Moreno JM, Rosa P et al. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010; 30: 407-412
    CrossrefPubMedGoogle Scholar
  • 31 Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008; 53: 121-138
    CrossrefPubMedGoogle Scholar
  • 32 Tufail A, Patel PJ, Sivaprasad S et al. Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) 2013; 27: 786
    CrossrefPubMedGoogle Scholar
  • 33 Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005; (4) CD004765
    PubMedGoogle Scholar
  • 34 Voykov B, Gelisken F, Inhoffen W et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years?. Graefes Arch Clin Exp Ophthalmol 2010; 248: 543-550
    CrossrefPubMedGoogle Scholar
  • 35 Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 2013; 33: 1375-1392
    CrossrefPubMedGoogle Scholar